John Harry Cross III - 07 Mar 2025 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role
Chief Financial Officer
Signature
/s/ Robert Cutler, attorney-in-fact
Issuer symbol
SNTI
Transactions as of
07 Mar 2025
Net transactions value
$0
Form type
4
Filing time
11 Mar 2025, 16:14:50 UTC
Previous filing
11 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNTI Stock Option (Right to Buy) Award $0 +174,200 $0.000000 174,200 07 Mar 2025 Common Stock 174,200 $3.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.